

Washington University School of Medicine

Digital Commons@Becker

2020-Current year OA Pubs

Open Access Publications

1-1-2022

Low-dose interleukin-2 reverses chronic migraine-related sensitizations through peripheral interleukin-10 and transforming growth factor beta-1 signaling

Zhaohua Guo

Jintao Zhang

Xuemei Liu

Jacqueline Unsinger

Richard S. Hotchkiss

See next page for additional authors


Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

 Part of the [Medicine and Health Sciences Commons](#)

Please let us know how this document benefits you.

Authors

Zhaohua Guo, Jintao Zhang, Xuemei Liu, Jacqueline Unsinger, Richard S. Hotchkiss, and Yu-Qing Cao



Original Research

Low-dose interleukin-2 reverses chronic migraine-related sensitizations through peripheral interleukin-10 and transforming growth factor beta-1 signaling

Zhaohua Guo^{a,b}, Jintao Zhang^{a,b,1}, Xuemei Liu^{a,b}, Jacqueline Unsinger^a,
Richard S Hotchkiss^{a,c,d}, Yu-Qing Cao^{a,b,*}

^a Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, United States

^b Washington University Pain Center, Washington University School of Medicine, St. Louis, MO, United States

^c Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States

^d Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States

ARTICLE INFO

Keywords:

Chronic migraine
Sensitization
Low-dose interleukin-2
Transforming growth factor beta-1
Interleukin-10
Trigeminal ganglion neuron

ABSTRACT

Low-dose interleukin-2 (LD-IL-2) treatment has been shown to effectively reverse chronic migraine-related behaviors and the sensitization of trigeminal ganglion (TG) neurons through expansion and activation of peripheral regulatory T cells (Tregs) in mice. In this study, we investigated the molecular mechanisms underlying the effects of LD-IL-2 and Treg cells. LD-IL-2 treatment increases the production of cytokines interleukin-10 (IL-10) and transforming growth factor beta-1 (TGFβ1) in T cells, especially Treg cells, suggesting that they may mediate the therapeutic effect of LD-IL-2. Indeed, neutralizing antibodies against either IL-10 or TGFβ1 completely blocked the effects of LD-IL-2 on the facial mechanical hypersensitivity as well as the sensitization of TG neurons resulting from repeated nitroglycerin (NTG, a reliable trigger of migraine in patients) administration in mice, indicating that LD-IL-2 and Treg cells engage both peripheral IL-10 and TGFβ1 signaling pathways to reverse chronic-migraine related sensitizations. In an *in vitro* assay, incubation of TG culture with exogenous IL-10 or TGFβ1 fully reversed NTG-induced sensitization of TG neurons, suggesting that the IL-10 and TGFβ1 signaling in TG neurons contribute to LD-IL-2's therapeutic effects. Collectively, these results not only elucidate the molecular mechanisms through which LD-IL-2 and Treg cells reverse chronic-migraine related sensitizations, but also suggest that the IL-10 and TGFβ1 signaling pathways in TG neurons are potential targets for chronic migraine therapy.

Introduction

With at least 15 headache days per month for at least 3 months, chronic migraine is highly debilitating and with limited treatment options (May and Schulte, 2016). Many patients are either unresponsive to current therapies or are intolerant to their side effects. There is an urgent need to develop better treatments and to understand their mechanisms of action.

A large body of clinical and animal studies support low-dose interleukin-2 (LD-IL-2) treatment as a safe and effective therapy for multiple autoimmune and neurological diseases, including chronic pain (Alves

et al., 2017; Davoli-Ferreira et al., 2020; Gao et al., 2017; Hu et al., 2021; Klatzmann and Abbas, 2015; Zhang et al., 2018). In a mouse model of chronic migraine, we have shown that LD-IL-2 treatment effectively reverses chronic migraine-related behaviors and prevents the sensitization of trigeminal ganglion (TG) neurons through expansion and activation of the endogenous regulatory T cells (Tregs) at peripheral tissues (Guo et al., 2021; Zhang et al., 2020).

Tregs are a subpopulation of CD4⁺ T cells that selectively express the transcription factor Foxp3 in the nucleus and high-affinity IL-2 receptors on the plasma membrane to outcompete other immune cells for IL-2 (Schmidt et al., 2012). They are known to employ multiple

* Corresponding author at: Department of Anesthesiology and Pain Center, Washington University School of Medicine, 660 South Euclid, Campus Box MSC 8054-86-05, St. Louis, MO 63110, United States.

E-mail address: caoy@anest.wustl.edu (Y.-Q. Cao).

¹ Present address: Department of Anesthesiology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.

<https://doi.org/10.1016/j.ynpai.2022.100096>

Received 29 April 2022; Received in revised form 1 June 2022; Accepted 10 June 2022

Available online 13 June 2022

2452-073X/© 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

mechanisms to suppress diverse types of immune cells (Schmidt et al., 2012), many of which have been implicated in migraine pathophysiology, including meningeal mast cells, dendritic cells, macrophages as well as microglia in the cervical/medullary dorsal horn (He et al., 2019; Levy et al., 2007; McIlvried et al., 2017; Reuter et al., 2001; Schain et al., 2018; Wieseler et al., 2017). To further validate LD-IL-2 and other Treg-targeted therapy [e.g. via activation of tumor necrosis factor receptor 2 on Treg cells (Fischer et al., 2019)] for chronic pain, we investigated the molecular mechanisms through which LD-IL-2 reverses chronic migraine-related behavioral and cellular sensitizations in the present study.

One of the main mechanisms that Treg cells use for immunosuppression is through the secretion of transforming growth factor beta-1 (TGF β 1), interleukin-10 (IL-10) and interleukin-35 (Sharabi et al., 2018). All of these cytokines, especially IL-10 and TGF β 1, have been shown to exhibit anti-nociceptive effects in various chronic pain models including neuropathic pain, back pain and pain related to experimental autoimmune encephalomyelitis (Chen et al., 2015; Duffy et al., 2019; Krukowski et al., 2016; Kwilasz et al., 2015; Laumet et al., 2020; Milligan et al., 2006; Zhang et al., 2017). In an attempt to determine the mechanism by which LD-IL-2 exerts its anti-migraine effects, we first examined whether LD-IL-2 treatment increases the production of IL-10 and TGF β 1 in T cells, especially Treg cells. Next, we modeled chronic migraine with repeated administration of nitroglycerin (NTG, a reliable migraine trigger in migraineurs) in mice and used neutralizing antibodies to investigate whether peripheral IL-10 and/or TGF β signaling pathways mediate the beneficial effects of LD-IL-2 on chronic migraine-related behaviors and the sensitization of TG neurons. Since both calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are strongly implicated in migraine pathophysiology (Messlinger and Russo, 2019), we used ratiometric Ca²⁺-imaging to identify TG neurons that respond to CGRP [i.e. CGRP-responsive (CGRP-R) neurons] and/or respond to PACAP [i.e. PACAP-responsive [(PACAP-R) neurons], respectively. This allowed us to investigate how IL-10 and TGF β signaling modulate the sensitization of TG neurons. Finally, because both IL-10 and TGF β 1 have been shown to activate their cognate receptors in primary afferent neurons to regulate ion channel expression and neuronal excitability (Chen et al., 2015; Laumet et al., 2020; Shen et al., 2013), we used *in vitro* assays to test whether exogenous TGF β 1 and/or IL-10 can directly block the sensitization of TG neurons resulting from repeated NTG administration.

Materials and methods

Mice

All experiments were carried out in accordance with the National Institutes of Health guide for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee at Washington University in St. Louis. All efforts were made to minimize mouse suffering, to reduce the number of mice used, and to utilize alternatives to *in vivo* techniques, if available. To avoid social isolation stress, all mice were group housed (2–5 per cage, same sex) in the animal facility of Washington University in St. Louis on a 12-hour light–dark cycle with constant temperature (23–24 °C), humidity (45–50%), and food and water *ad libitum*. All experiments were performed during the light phase (9 am to 4 pm). Female outbred Swiss Webster mice (8–15 weeks old, purchased from Charles River) were used in the majority of experiments. Female C57BL/6 mice (8–15 weeks old, generated from our mouse colony) were used in the behavioral assays (Fig. 2) when shipment of mice was not feasible in 2020. Our previous work indicates that both strains exhibit similar behavioral and neuronal responses to repeated NTG and LD-IL-2 treatment (Guo et al., 2021; Zhang et al., 2020).

To differentiate between Foxp3⁺ Treg cells and CD4⁺ T helper cells, we used female DEREg (depletion of regulatory T cell) mice on C57BL/6

background for the intracellular staining of TGF β 1 and flow cytometry experiment (Fig. 1B–E). DEREg mice contain a transgenic allele that expresses the diphtheria toxin receptor-enhanced green fluorescent protein (DTR-EGFP) fusion protein under the control of the genomic sequences that regulate the expression of transcription factor *foxp3* (Lahl et al., 2007). DEREg breeders (32050, Jackson Laboratory, Bar Harbor, ME) were crossed with C57BL/6 mice to generate heterozygotes as a reporter line for Foxp3⁺ Treg cells.

IL-10 ELISA (enzyme-linked immunosorbent assay)

Female Swiss Webster mice received daily intraperitoneal (i.p.) injections of saline or LD-IL-2 for 5 consecutive days. Splenocytes were dissociated in HBSS buffer (with Ca²⁺ and Mg²⁺) containing 1% glutamine, 1% non-essential amino acids (NEAA), 2% fetal bovine serum (FBS) and 25 U/ μ l DNase. Cells were filtered through a sterile 70- μ m cell strainer. After lysis of red blood cells (Biologend, 420301, San Diego, CA), cells were pelleted and resuspended in RPMI1640 media (Invitrogen, Waltham, MA) for ELISA. Live cells were counted by the Vi-CELL Automated Cell Viability Analyzer (Beckman Coulter, Brea, CA).

Splenocytes were plated in 24-well plates (5 \times 10⁶ live cells per well) and stimulated overnight at 37 °C with antibodies against CD3 (1 μ g/ml, Biologend, 100340, clone 145-2C11) and CD28 (5 μ g/ml, Biologend, 102116, clone 37.51) in 1 ml complete RPMI1640 media containing 10% FBS, 1% glutamine, 1% NEAA and penicillin/streptomycin. IL-10 in the supernatants (50 μ l per sample) were quantified by ELISA according to manufacturer's instructions (Biologend, 431411).

Intracellular staining of TGF β 1 and flow cytometry

Splenocytes were prepared from female DEREg mice after daily i.p. injections of saline or LD-IL-2 for 5 consecutive days and were plated in 24-well plates (5 \times 10⁶ live cells per well) in 1 ml complete RPMI1640 media containing 10% FBS, 1% glutamine, 1% NEAA, penicillin/streptomycin and 5 μ g/ml brefeldin A (Biologend, 420601) to block the secretion and to increase the intracellular accumulation of TGF β 1. After 4 h incubation at 37 °C, cells were stained with antibodies that recognize cell surface marker CD4 (Biologend, clone GK1.5) for 30 min. Subsequently, cells were incubated in fixation buffer (Biologend, 420801) for 20 min, blocked with anti-CD16/32 (Biologend, 101310, clone 93) for 10 min, and were stained with the anti-mouse TGF β 1 antibody (Biologend, clone TW7-16B4) in the intracellular staining permeabilization wash buffer (Biologend, 421002) for 20 min. The frequency of individual cell subpopulations was determined via flow cytometric analysis. Data were collected with FACScan (Becton Dickinson Dickinson, Franklin Lakes, NJ) and analyzed with the CellQuest Pro (Becton Dickinson) and Rainbow X Alias (Cytek, Fremont, CA) software.


Mouse model of chronic migraine and drug treatments

To model chronic migraine, mice received repetitive i.p. injections of NTG (10 mg/kg and 10 ml/kg in saline with 1% propylene glycol) once every 2 days for 5 or more times as described previously (Guo et al., 2021; Zhang et al., 2020). The control mice received vehicle (saline with 1% propylene glycol, 10 ml/kg) injections every 2 days. NTG (SDM27, Copperhead Chemical, Tamaqua, PA) was freshly diluted from the stock (10% in propylene glycol, aliquoted in airtight glass vials, stored at room temperature and kept in darkness) with saline for every injection.

To reverse NTG-induced sensitization, mice received i.p. injections of 1 μ g IL-2 in 100 μ l saline every day for 11 days, starting 1 day after the 2nd NTG injection (Zhang et al., 2020). The control mice received daily i.p. injections of 100 μ l saline. Recombinant mouse IL-2 (carrier-free; Biologend) was freshly diluted from the stock (0.5–1 mg/ml aliquots at –80 °C) every day.

The neutralizing antibody against IL-10 [200 μ g/mouse, BE0049, BioXcell, Labanon, NH (Li et al., 2012)] or control immunoglobulin G

A IL10 ELISA



B-G TGFβ1 intracellular staining and flow cytometry

B Gating strategy





Fig. 1. LD-IL-2 treatment increases the production of IL-10 and TGFβ1 in splenocytes. (A) The amount of IL-10 in culture supernatant in response to anti-CD3 and anti-CD28 stimulation measured by ELISA (n = 5 and 7 in saline and LD-IL-2 groups, respectively). *p < 0.05, two-tailed t test. (B) Gating strategy for individual cell populations. (C-E) The frequencies of TGFβ1⁺ cells (C), TGFβ1⁺EGFP⁺ cells (D), and TGFβ1⁺EGFP⁻ cells (E) among CD4⁺ splenocytes from saline- and ld-il-2-treated DEREK mice (n = 10 and 12 in saline and LD-IL-2 groups, respectively). *p < 0.05, two-tailed t test. (F-G) The number (F) and the frequency (G) of CD4⁺ cells in total splenocytes in R1 (gated for lymphocytes) from saline- and LD-IL-2-treated DEREK mice (same as in B-D).

(IgG, BioXcell, BE0088) was i.p. injected every 2 days. The neutralizing antibody against all TGFβ isoforms [200 μg/mouse, BioXcell, BE0057, (Littwitz-Salomon et al., 2018)] or control IgG (BioXcell, BE0083) was i. p. injected every 3 days.

Behavioral test – withdrawal responses to facial mechanical stimuli

Mice were extensively handled by the experimenters for 2 weeks and were well-habituated to the test room and the test apparatus before each experiment. The experimenters were blinded to the treatments mice received during data collection and analysis.

The hair on the mouse forehead (above and between the eyes) was shaved the day before testing. On the test day, the experimenter gently held the mouse on the palm with minimal restraint and applied the calibrated von Frey filament (Bioseb, Pinellas Park FL) perpendicularly to the shaved skin, causing the filament to bend for 5 s. A positive response was determined by the following criteria as previously described: mouse vigorously stroked its face with the forepaw, head withdrawal from the stimulus, or head shaking (Zhang et al., 2020). The up-down paradigm was used to determine the 50% withdrawal threshold (Chaplan et al., 1994). The withdrawal thresholds to facial von Frey stimuli were measured at baseline and two days after each NTG injection.

Primary culture of mouse TG neurons and drug treatments

TG tissues were collected and were treated with 2.5 mg/ml collagenase IV in HBSS solution without serum (Invitrogen) for 10 min, followed by 2.5 mg/ml trypsin in HBSS solution without serum at 37 °C for 15 min. Cells were dissociated by triturating with fire-polished glass pipettes, resuspended in MEM-based culture medium (Invitrogen) containing 5% FBS, 25 ng/ml nerve growth factor (R&D, Minneapolis, MN), 10 ng/ml glial cell-derived neurotrophic factor (R&D), and seeded on Matrigel-coated coverslips. The media did not contain penicillin/streptomycin. Ratiometric Ca²⁺ imaging was performed at 2 days *in vitro*.

In three experiments, recombinant mouse TGFβ1 (R&D, 7666-MB, 2, 10 or 50 ng/ml) and/or recombinant mouse IL-10 (R&D, 417-ML, 0.2, 1 or 50 ng/ml) were added to the culture media at 1 day *in vitro*. After overnight incubation, neurons were used for Ca²⁺ imaging.

Ratiometric Ca²⁺ imaging

TG cultures were incubated with HBSS/HEPES solution containing 2.5 μM Ca²⁺ indicator Fura-2 AM and 10% Pluronic F-68 (both from Molecular Probes, Eugene, OR) at 37 °C for 45 min. De-esterification of the dye was carried out by washing the coverslips 3 times with HBSS/HEPES solution and incubating the coverslips in HBSS/HEPES solution in the dark for an additional 15 min at 37 °C. Neurons were used for Ca²⁺ imaging experiments within 1 h after Fura-2 loading as in our previous study (Guo et al., 2021).

Coverslips were placed in a flow chamber mounted on a Nikon TE2000S inverted epifluorescent microscope and were perfused with room temperature Tyrode's solution (1 ml/min) containing (in mM): 130 NaCl, 2 KCl, 2 CaCl₂, 2 MgCl₂, 25 Hepes, 30 glucose, pH 7.3–7.4 with NaOH, and 310 mosmol/kgH₂O. Healthy neurons were chosen based on their differential interference contrast images (Guo et al., 2021). Coverslips were alternately excited by 340 and 380 nm light (Sutter Lambda LS, Sutter Instrument, Navato, CA) and the emission was detected at 510 ± 20 nm by a UV-transmitting 20x objective (N.A. 0.75) and a Prime BSI Express sCMOS camera (Photometrics, Tuscon AZ). The frame capture period was 50 ms at 1.5 s interval. MetaMorph software (Molecular Devices, San Jose, CA) was used for controlling and synchronizing the devices as well as image acquisition and analysis.

Regions of interest (ROIs) encompassing individual neurons were defined *a priori*. The ratio of fluorescence excited by 340 nm divided by fluorescence excited by 380 nm (R_{340/380}) was determined on a pixel-by-pixel basis and was averaged for each ROI. An additional background area was recorded in each field for off-line subtraction of background fluorescence. Peak responses (ΔF) were determined by calculating the relative increase in R_{340/380} above baseline (F₀, the average R_{340/380} during the 2–3 min baseline measurement). A ΔF/F₀ > 20% was set as the threshold for a response.

After a 2–3 min baseline measurement in Tyrode's solution, neurons were perfused with 50 nM PACAP₁₋₃₈ (Tocris, Minneapolis, MN, 1136) for 1 min followed by washing with Tyrode's for 4 min. Subsequently, the coverslip was incubated with 3 μM human αCGRP (Tocris, 3012) for

1 min followed by washing with Tyrode's for 4 min. CGRP and PACAP were freshly diluted from the stock (aliquots at –80 °C) in Tyrode's solution before each experiment.

Statistical analysis

For behavioral experiments, power analysis was conducted to estimate sample size with > 80% power to show an effect size of 0.8, alpha (two-sided) of 0.05, and a simple covariance structure for repeated measures. The experimenters were blinded to the treatments mice received. For Ca²⁺ imaging, all groups were tested in parallel in individual experiments. Each group contained neurons from at least 3 batches of culture.

All data were reported as mean ± standard error of the mean. Shapiro–Wilk test showed that all data were normally distributed. Statistical significance between or within experimental groups was assessed in Origin10 (OriginLab Corporation, Northampton, MA) or Statistica (StatSoft Inc, Tulsa, OK). Two-tailed *t*-test was used to analyze ELISA and flow cytometry data. The non-parametric Friedman test or Kruskal–Wallis ANOVA on ranks with multiple comparisons (Student–Newman–Keuls method) was used to analyze the differences in the withdrawal threshold to mechanical stimuli. The χ² test followed by post hoc Fisher's exact test with Bonferroni correction were used to compare the distribution of TG subpopulations between various treatment groups. Differences with *p* < 0.05 were considered statistically significant. The statistical analysis for individual experiments was described in figure legends.

Results

LD-IL-2 treatment increases the production of IL-10 and TGFβ1 in splenocytes

In a previous study, we found that treating naïve mice with LD-IL-2 doubles the number of Treg cells in the spleen without altering the total number of CD4⁺ T helper cells or CD3⁺ lymphocytes (Zhang et al., 2020). In this study, we examined whether LD-IL-2 treatment alters the production of IL-10 and TGFβ1 in mice, as both cytokines are secreted by Treg cells and have been shown to reverse chronic pain-related behaviors in rodent models (Chen et al., 2015; Krukowski et al., 2016; Kwilasz et al., 2015; Laumet et al., 2020; Milligan et al., 2006; Zhang et al., 2017). We used ELISA to compare the amount of IL-10 secreted by splenocytes from mice that received daily injections of saline or LD-IL-2 for 5 consecutive days. IL-10 was not detectable in supernatants of unstimulated splenocytes (Fig. 1A). After overnight stimulation with anti-CD3 and anti-CD28 antibodies, splenocytes from saline-treated mice produced 326 ± 79 pg/ml IL-10 in the supernatant, likely secreted from stimulated Treg and other T cells (Fig. 1A). Stimulated splenocytes from LD-IL-2-treated mice produced 799 ± 207 pg/ml IL-10 in the supernatant (Fig. 1A). On average, LD-IL-2 treatment led to a 2.5-fold increase in IL-10 secretion. This likely results from the higher number of Treg cells in splenocytes after LD-IL-2 treatment.

Among all 3 TGFβ isoforms, TGFβ1 predominantly mediates Treg-induced suppression (Moreau et al., 2022). However, many other types of cells in the spleen also produce TGFβ1 in addition to Tregs. Since supernatants of unstimulated splenocytes from naïve mice already contained high level of TGFβ1 (2298 ± 148 pg/ml, *n* = 5 female Swiss Webster mice), the effect of LD-IL-2 on TGFβ1 production may be masked in the ELISA test. We therefore used intracellular staining and flow cytometry to measure the number of Treg cells and other CD4⁺ T helper cells that express TGFβ1. Female DREG mice received daily injections of saline or LD-IL-2 for 5 consecutive days. Splenocytes were collected to stain for intracellular TGFβ1. T helper cells were identified by the anti-CD4 antibody. Foxp3⁺ Treg cells were identified by the EGFP signal (Lahl et al., 2007; Zhang et al., 2020). LD-IL-2 treatment significantly increased the frequency of TGFβ1⁺ cells among CD4⁺ cells

(Fig. 1B). In particular, the percentage of EGFP⁺ Treg cells that express TGFβ1 was increased with treatment (Fig. 1C). Conversely, LD-IL-2 did not alter the percentage of EGFP-negative T helper cells that express TGFβ1 (Fig. 1D) or the total number of CD4⁺ cells in the spleen (Fig. 1E). Together, these results indicate that LD-IL-2 treatment increases the production of IL-10 and TGFβ1 in splenocytes. In a previous study, we have shown that 2 weeks of ld-IL-2 treatment leads to a 4–9 fold increase in the number of Treg cells in dura and TG (Zhang et al., 2020), it is highly likely that ld-IL-2 upregulates the production of IL-10 and TGFβ1 in these tissues.

LD-IL-2 blocks NTG-induced behavioral sensitization through both peripheral TGFβ and IL-10 signaling pathways

To test whether endogenous IL-10 and/or TGFβ1 mediate the therapeutic effects of LD-IL-2, we treated female C57BL/6 mice with neutralizing antibodies against IL-10 or against all TGFβ isoforms to inhibit peripheral IL-10 or TGFβ signaling. Baseline mechanical thresholds were not altered by the neutralizing antibodies (Fig. 2A, day 1 versus day 3). Repeated NTG administration (10 mg/kg, i.p., every 2 days) still produced robust and long-lasting facial mechanical hypersensitivity in the presence of neutralizing antibodies (Fig. 2A, day 5–7 versus day 1–3), indicating that the peripheral TGFβ or IL-10 signaling pathway is not involved in basal mechanical nociception or the development of NTG-induced behavioral sensitization.

Next, we investigated how the neutralizing antibodies affect LD-IL-2's effect on NTG-induced behavioral sensitization. First, we confirmed that NTG-induced persistent facial mechanical hypersensitivity in female C57BL/6 mice could be completely reversed after 3 daily LD-IL-2 injections (Fig. 2B, NTG+IL-2 group, day 3 to 7), consistent with previous reports (Guo et al., 2021; Zhang et al., 2020). Moreover,

subsequent NTG injections failed to establish persistent mechanical hypersensitivity on facial skin as long as the LD-IL-2 treatment was continued (Fig. 2B, NTG+IL-2 group, day 7 to 15), indicating that LD-IL-2 prevents the development of chronic migraine-related behaviors as well as reversed the established sensitization. Co-administration of control IgGs during LD-IL-2 treatment did not alter the effects of LD-IL-2 (Fig. 2B, NTG+IL-2+control IgG group). In contrast, the effect of LD-IL-2 was completely abolished in mice that received neutralizing antibody against IL-10 (Fig. 2B, NTG+IL-2+anti-IL-10 Ab group), and NTG-induced facial mechanical hypersensitivity persisted throughout the experiment. Thus, although peripheral IL-10 signaling is not involved in the development of NTG-induced sensitization (Fig. 2A), it is required for the reversal of repeated NTG-induced hypersensitivity by LD-IL-2 (Fig. 2B).

Likewise, the neutralizing antibody against all TGFβ isoforms also completely blocked the effects of LD-IL-2 (Fig. 2B, NTG+IL-2+anti-TGFβ Ab group), indicating that peripheral TGFβ signaling does not contribute to NTG-induced hypersensitivity (Fig. 2A), but mediates the anti-migraine effects of LD-IL-2 (Fig. 2B). Collectively, these results support that LD-IL-2 needs to engage both peripheral IL-10 and TGFβ signaling pathways to reverse NTG-induced sensitization.

LD-IL-2 treatment blocks NTG-induced cellular sensitization through both peripheral IL-10 and TGFβ signaling pathways

In our previous study, LD-IL-2 not only reverses NTG-induced behavioral sensitization, but also prevents repeated NTG-induced increase in the number of TG neurons that respond to neuropeptides CGRP and PACAP (Guo et al., 2021; Zhang et al., 2020). Here, we asked whether peripheral IL-10 and TGFβ signaling pathways mediate the effects of LD-IL-2 on NTG-induced sensitization of TG neurons. As in our




Fig. 2. LD-IL-2 blocks NTG-induced behavioral sensitization through both peripheral IL-10 and TGFβ signaling pathways. (A) Female C57BL/6 mice received i.p. injections of neutralizing antibodies against IL-10 or TGFβ (anti-IL-10 Ab or anti-TGFβ Ab, 200 μg/mouse) before and during repeated NTG administration (n = 4 mice/group). Arrows indicate the injections of antibodies or NTG. On the days that the mouse behaviors were tested, NTG and/or the antibodies were always injected after completing the behavioral tests. Friedman test: p < 0.05 within the anti-TGFβ Ab group (F[3, 12] = 57.24); post hoc Student-Newman-Keuls test: ***p < 0.001, compared with the day 1 and 3 thresholds. Friedman test: p < 0.05 within the anti-IL-10 Ab group (F[3, 12] = 81.60); ###p < 0.001, compared with the day 1 and 3 thresholds. (B) The effect of LD-IL-2 on NTG-induced facial skin hypersensitivity was abolished by anti-IL-10 Ab and anti-TGFβ Ab. Arrows indicate the injection of NTG, LD-IL-2, anti-TGFβ Ab, anti-IL-10 Ab or control IgGs. On the days that the mouse behaviors were tested, drugs were always injected after completing the behavioral tests (n = 6 female C57BL/6 mice/group). In the NTG+IL-2+control IgG group, 3 mice received control IgG for anti-TGFβ Ab and the other 3 received the control IgG for anti-IL-10 Ab. Kruskal-Wallis ANOVA on ranks: p < 0.05 for group (F[3, 160] = 147.7), p < 0.001 for time (F[7, 160] = 68.3), and p < 0.001 for group × time interaction (F[21, 160] = 14.6); post hoc Student-Newman-Keuls test: ***p < 0.001, NTG+IL-2+anti-TGFβ Ab versus the corresponding NTG+IL-2 and NTG+IL-2+control IgG groups; ###p < 0.001, NTG+IL-2+anti-IL-10 Ab versus the corresponding NTG+IL-2 and NTG+IL-2+control IgG groups; §§§p < 0.001, compared with the baseline threshold (day 1) in the NTG+IL-2 group; †††p < 0.001, compared with the baseline threshold in the NTG+IL-2+control IgG group; †††p < 0.001, compared with the baseline threshold in the NTG+IL-2+anti-TGFβ Ab group; †††p < 0.001, compared with the baseline threshold in the NTG+IL-2+anti-IL-10 Ab group.

previous study, bath application of 50 nM PACAP₁₋₃₈ and 3 μ M α CGRP evoked significant intracellular Ca²⁺ increase in cultured TG neurons (Fig. 3A-B). This allowed us to define CGRP-R and PACAP-R neurons as well as neurons that respond to both CGRP and PACAP (CGRP-R&PACAP-R) in TG cultures.

Female Swiss Webster mice received vehicle or 10 mg/kg NTG injections every 2 days for 7 times. Two days after the last injection, we cultured TG neurons and measured CGRP- and PACAP-induced intracellular Ca²⁺ increase in individual neurons (Fig. 4A). The number of CGRP-R and PACAP-R neurons was significantly higher in TG cultures from NTG-treated mice than those from vehicle controls (Fig. 4B-C), indicating sensitization of TG neurons as in our previous work (Guo et al., 2021). In parallel experiments, we treated another four groups of mice with anti-IL-10 or anti-TGF β antibody during repeated vehicle- or NTG-injections (Fig. 4A). This did not change the number of CGRP-R or PACAP-R neurons in TG cultures from either vehicle- or NTG-treated mice (Fig. 4B-C). We also plotted the CGRP-R and PACAP-R TG subpopulations in Venn diagrams to indicate CGRP-R&PACAP-R neurons (Fig. 4D). Repeated NTG administration resulted in 3.8-fold increase in CGRP-R&PACAP-R neurons in TG culture (from 5.4% to 20.7% of total TG neurons, $p < 0.001$, χ^2 test followed by post hoc Fisher's exact test with Bonferroni correction). This was not altered by anti-IL-10 or anti-TGF β antibodies either (Fig. 4D). These data suggest that peripheral IL-10 and TGF β signaling pathways are not involved in the regulation of basal TG neuron activity or the establishment of NTG-induced sensitization of TG neurons.

As shown in our previous work (Guo et al., 2021), NTG-induced increase in CGRP-R and PACAP-R TG neurons was blocked by LD-IL-2 treatment (Fig. 5A-C, NTG versus NTG+IL-2 groups), supporting that LD-IL-2 prevents the sensitization of TG neurons. In cultures from mice that received the anti-IL-10 antibody along with LD-IL-2 treatment, the percentages of CGRP-R and PACAP-R TG neurons were comparable to those of NTG-treated mice (Fig. 5B-D, NTG+IL-2 versus NTG+IL-2+anti-IL-10 Ab groups). The percentages of CGRP-R and PACAP-R TG neurons in cultures from mice that received the anti-TGF β antibody along with LD-IL-2 treatment were also similar to those of NTG-treated mice (Fig. 6A-D). In addition, LD-IL-2 suppressed NTG-induced increase in CGRP-R&PACAP-R neurons, and this effect was also negated by the anti-IL-10 antibody (Fig. 5D, $p < 0.01$, χ^2 test followed by post hoc Fisher's exact test with Bonferroni correction) and the anti-TGF β

antibody (Fig. 6D, $p < 0.01$, χ^2 test followed by post hoc Fisher's exact test with Bonferroni correction). Taken together, both neutralizing antibodies abolish the effects of LD-IL-2 but not the effects of NTG on TG neurons, suggesting that neither peripheral IL-10 nor TGF β signaling contributes to NTG-induced sensitization of TG neurons (Fig. 4), but both pathways are required for LD-IL-2 to reverse NTG-induced peripheral sensitization (Figs. 5-6).

Activation of IL-10 and/or TGF β 1 signaling pathways in TG neurons reverses repeated NTG-induced neuronal sensitization.

Receptors for TGF β 1 and IL-10 are expressed in primary afferent neurons (Chen et al., 2015; Laumet et al., 2020; Shen et al., 2013). To investigate whether TGF β 1 and/or IL-10 can directly regulate NTG-induced cellular sensitization through activation of their cognate receptors on primary afferent neurons, we cultured mouse TG neurons after 5 repeated vehicle or NTG administrations and incubated neurons in media containing recombinant TGF β 1 [50 ng/ml, (Liu et al., 2006)] and/or IL-10 [50 ng/ml, (Komai et al., 2018)] overnight. Either TGF β 1 or IL-10 at high concentration significantly reduced the number of CGRP-R and PACAP-R neurons in TG cultures from NTG-treated mice (Fig. 7A-B, NTG groups). The reduction of CGRP-R and PACAP-R TG neurons in cultures from vehicle-treated mice did not reach statistical significance (Fig. 7A-B, vehicle groups). Cultures treated with both TGF β 1 and IL-10 did not show further decrease in CGRP-R and PACAP-R neurons (Fig. 7, TGF β 1 + IL-10 groups). In cultures from vehicle-treated mice, the percentage of CGRP-R&PACAP-R TG neurons was not reduced by IL-10 but was significantly reduced by TGF β 1 and TGF β 1 + IL-10 (Fig. 7C, left column, $p < 0.01$, compared with the untreated group, χ^2 test followed by post hoc Fisher's exact test with Bonferroni correction). In contrast, the number of CGRP-R&PACAP-R TG neurons in cultures from NTG-treated mice was drastically decreased by TGF β 1 and IL-10, either alone or in combination (Fig. 7C, right column, $p < 0.001$, χ^2 test followed by post hoc Fisher's exact test with Bonferroni correction).

In the next experiment, we treated TG cultures with lower concentrations of TGF β 1 [10 ng/ml, (Chen et al., 2015; Zhang et al., 2017)] and/or IL-10 [1 ng/ml, (Krukowski et al., 2016; Laumet et al., 2020; Shen et al., 2013)]. This did not alter the percentage of CGRP-R and PACAP-R TG neurons from vehicle-treated mice (Fig. 8A-B, vehicle groups), but significantly reduced the numbers of CGRP-R and PACAP-R




Fig. 3. Representative traces and images of PACAP-R and CGRP-R TG neurons. (A) The protocol to measure PACAP- and CGRP-evoked intracellular Ca²⁺ increase and the representative traces of PACAP- and CGRP-induced Ca²⁺ transients in TG neurons. (B) Representative images of Fura-2-loaded TG neurons before, during and after applications of 50 nM PACAP and 3 μ M CGRP, respectively. The arrows indicate the same CGRP-R, PACAP-R and CGRP-R&PACAP-R neurons shown in A, respectively.




Fig. 4. Peripheral IL-10 or TGFβ signaling pathway does not regulate the number of CGRP-R and PACAP-R TG neurons at basal level or after repeated NTG administration. (A) Time line of the experiment in B-D. Data from individual experimental groups in Figs. 4-6 were collected in parallel but plotted separately for clarity. (B) The percentages of CGRP-R neurons in TG cultures from female Swiss Webster mice after repeated injections of vehicle, NTG as well as neutralizing antibodies against IL-10 or TGFβ (n = 3-6 mice/group). The number of neurons in each group is indicated in the figure. ***p < 0.001, χ^2 test followed by post hoc Fisher's exact test with Bonferroni correction. (C) The percentages of PACAP-R neurons in TG cultures from vehicle- or NTG-treated mice (same neurons as in B). ***p < 0.001, χ^2 test followed by post hoc Fisher's exact test with Bonferroni correction. (D) Venn diagrams of the percentages of CGRP-R and PACAP-R neurons in each group (same neurons as in B).




Fig. 5. The IL-10 neutralizing antibody abolishes the effects of LD-IL-2 on NTG-induced sensitization of TG neurons. (A) Time line of the experiment in B-D. (B) The percentages of CGRP-R neurons in TG cultures from female Swiss Webster mice that received repeated NTG, LD-IL-2 as well as anti-IL-10 antibody or control IgG ($n = 5-8$ mice/group). The number of neurons in each group is indicated in the figure. The vehicle and NTG groups are the same as in Fig. 4B. $*** p < 0.001$, χ^2 test followed by post hoc Fisher's exact test with Bonferroni correction. (C) The percentages of PACAP-R neurons in TG cultures from female Swiss Webster mice that received repeated NTG, LD-IL-2 as well as anti-IL-10 antibody or control IgG (same neurons as in B). The vehicle and NTG groups are the same as in Fig. 4C. $*** p < 0.001$, χ^2 test followed by post hoc Fisher's exact test with Bonferroni correction. (D) Venn diagrams of the percentages of CGRP-R and PACAP-R neurons in the NTG+IL-2 groups (same neurons as in B).

neurons in TG cultures from NTG-treated mice to the control level (Fig. 8A-B, NTG groups). Incubation of TG cultures from NTG-treated mice with 2 ng/ml TGF β 1 and 0.2 ng/ml IL-10 did not reverse NTG-induced cellular sensitization (Fig. 8C-D). Together, these data suggest that LD-IL-2 engages both TGF β 1 and IL-10 signaling pathways in TG neurons to reverse NTG-induced increase in the numbers of functional CGRP and PACAP receptors.

Discussion

Our recent studies show that peripheral Treg cells mediate the therapeutic effects of LD-IL-2 in mouse models of chronic headache disorders (Guo et al., 2021; Zhang et al., 2020). In the present work, we progressed to elucidate the molecular mechanisms through which LD-IL-2 and Treg cells reverse chronic migraine-related behavioral and cellular sensitizations in mice. First, we confirmed that LD-IL-2 treatment increases the production of IL-10 and TGF β 1 in T cells, especially Treg cells, from the spleen. Since LD-IL-2 results in a higher magnitude of Treg increase in dura and TG (4-9 fold) than in the spleen [2-fold,

(Zhang et al., 2020)], it is highly likely that the secretion of both IL-10 and TGF β 1 are upregulated by LD-IL-2 treatment in TG and dura. IL-2-activated Treg cells may also induce the secretion of IL-10 and TGF β 1 from macrophages and other cells (Schmidt et al., 2012; Sharabi et al., 2018). More work is needed to determine the levels of IL-10 and TGF β 1 in serum, TG and dura after LD-IL-2 treatment; and to investigate whether Treg cells are the main source of IL-10 and TGF β 1 in TG and dura.

Previous studies indicate that activation of either IL-10 or TGF β 1 signaling pathway is sufficient to exert anti-hyperalgesic effects in animal models of chronic somatic pain (Chen et al., 2015; Krukowski et al., 2016; Kwilasz et al., 2015; Laumet et al., 2020; Milligan et al., 2006; Zhang et al., 2017). Our work shows that IL-10 and TGF β signaling pathways do not contribute to NTG-induced sensitizations. However, treating mice with either neutralizing antibodies against IL-10 or TGF β completely blocked the effects of LD-IL-2 on chronic migraine-related behaviors and the sensitization of TG neurons. Thus, LD-IL-2 no longer exhibits anti-migraine effects when IL-10 signaling is inhibited and TGF β signaling is unperturbed, or vice versa. This led us to conclude that both




Fig. 7. The effect of high concentrations of TGFβ1 and/or IL-10 on NTG-induced neuronal sensitization. (A) The percentages of CGRP-R neurons in TG cultures from female Swiss Webster mice that received repeated vehicle or NTG (n = 4–7 mice/group). The number of neurons in each group and the overnight treatment conditions are indicated in the figure. **p < 0.01. ***p < 0.001, χ^2 test followed by post hoc Fisher’s exact test with Bonferroni correction. (B) The percentages of PACAP-R neurons in TG cultures from female Swiss Webster mice that received repeated vehicle or NTG (same neurons as in A). ***p < 0.001, χ^2 test followed by post hoc Fisher’s exact test with Bonferroni correction. (C) Venn diagrams of the percentages of CGRP-R and PACAP-R neurons in each group (same neurons as in A and B).

human primary afferent neurons as well, given that the expression of IL-10 receptor α subunit in human DRG neurons is broader than that in mice (Tavares-Ferreira et al., 2022). One of the limitations of this study is that we did not generate full dose–response curves of TGFβ1- and IL-10-regulation of CGRP-R and PACAP-R TG neurons, making it difficult to assess the interactions between these two signaling pathways. Future in-depth studies are warranted to investigate whether TGFβ1 and IL-10 signaling synergistically regulate the level of functional CGRP and PACAP receptors in TG neurons under chronic migraine-related state, as in the case of TGFβ1- and IL-10-mediated modulation of metabolic signals in humoral immunity (Komai et al., 2018). Another caveat is that, although the selectivity of neutralizing antibodies are well documented,

it remains to be tested whether inhibition of TGFβ1 signaling indirectly affects the strength of IL-10 signaling, or vice versa.

Female inbred and outbred mice were used in the present study as migraine is far more common in women than in men, and female sex increases the risk of chronic migraine (Ashina et al., 2021; May and Schulte, 2016). LD-IL-2 reverses chronic migraine-related sensitizations in both male and female, inbred and outbred mice through peripheral Treg cells (Zhang et al., 2020). It is likely that the effects of LD-IL-2 in male mice are also mediated through peripheral TGFβ1 and IL-10 signaling pathways but this requires further assessment.

Repeated NTG administration is widely used to establish a chronic migraine-related state in rodents (Guo et al., 2021; Pradhan et al., 2014;




Fig. 8. The effect of low concentrations of TGFβ1 and/or IL-10 on NTG-induced neuronal sensitization. (A-B) The percentages of CGRP-R neurons (A) and PACAP-R neurons (B) in TG cultures from female Swiss Webster mice that received repeated vehicle or NTG ($n = 3-5$ mice/group). Cultures were treated with 10 ng/ml TGFβ1 and/or 1 ng/ml IL-10 overnight. The number of neurons in each group and the overnight treatment conditions are indicated in the figure. * $p < 0.05$. ** $p < 0.01$, χ^2 test followed by post hoc Fisher's exact test with Bonferroni correction. (C-D) The percentages of CGRP-R neurons (C) and PACAP-R neurons (D) in TG cultures from female Swiss Webster mice that received repeated NTG ($n = 3$ mice/group). Cultures were treated with 2 ng/ml TGFβ1 and/or 0.2 ng/ml IL-10 overnight.

Sufka et al., 2016; Tipton et al., 2016; Zhang et al., 2020). However, the dose of NTG required to establish persistent behavioral sensitization and hyperalgesic priming in naïve mice is much higher than that used to trigger migraine-like headache in migraine patients (Olesen, 2008), and it only models one of the many mechanisms underlying migraine pathophysiology. Future studies need to investigate whether peripheral IL-10 and TGFβ1 signaling mediate LD-IL-2's effects on chronic migraine-related sensitizations generated through other mechanisms.

In addition to the release of IL-10 and TGFβ1, Treg cells employ many other mechanisms to mediate immunosuppression, for example, the release of interleukin-35, the metabolism of extracellular ATP to adenosine by CD39 and CD73, as well as the PD-1/PD-L1 co-inhibitory pathway (Schmidt et al., 2012; Sharabi et al., 2018). All of these mechanisms have been shown to contribute to the regulation of chronic pain (Chen et al., 2017; Duffy et al., 2019; Luongo et al., 2021). Whether LD-IL-2 and Treg cells engage these mechanisms to inhibit chronic migraine-related behavioral and cellular sensitizations merits further investigation.

Taken together, the present study reveals the molecular mechanisms through which LD-IL-2 and Treg cells reverse chronic-migraine related behavioral and cellular sensitizations, providing further support for future clinical assessment of LD-IL-2 as a treatment for chronic migraine. Moreover, our results suggest that the TGFβ1 and IL-10 signaling pathways in TG neurons can be targeted for chronic migraine therapy.

Data availability statement

Raw data is available upon request to the corresponding author.

Funding

This work was supported by the Department of Defense Investigator-Initiated Research Award W81XWH2110597 to YQC. The sponsor was not involved in any of the stages from study design to submission of the paper for publication.

CRediT authorship contribution statement

Zhaohua Guo: Conceptualization, Data curation, Formal analysis, Methodology, Visualization. **Jintao Zhang:** Data curation, Formal analysis, Methodology, Visualization. **Xuemei Liu:** Data curation, Formal analysis, Methodology, Visualization. **Jacqueline Unsinger:** Data curation, Formal analysis, Methodology, Visualization. **Richard S Hotchkiss:** Conceptualization, Supervision, Visualization. **Yu-Qing Cao:** Conceptualization, Funding acquisition, Project administration, Supervision, Validation, Visualization.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence

the work reported in this paper.

Acknowledgements

The authors thank Dr. Drew Walton for valuable comments on the manuscript.

References

- Alves, S., Churlaud, G., Audrain, M., Michaelsen-Preusse, K., Fol, R., Souchet, B., Braudeau, J., Korte, M., Klatzmann, D., Cartier, N., 2017. Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice. *Brain* 140 (3), 826–842.
- Ashina, M., Katsarava, Z., Do, T.P., Buse, D.C., Pozo-Rosich, P., Ozge, A., Krymchantowski, A.V., Lebedeva, E.R., Ravishankar, K., Yu, S., Sacco, S., Ashina, S., Younis, S., Steiner, T.J., Lipton, R.B., 2021. Migraine: epidemiology and systems of care. *Lancet* 397 (10283), 1485–1495.
- Chaplan, S.R., Bach, F.W., Pogrel, J.W., Chung, J.M., Yaksh, T.L., 1994. Quantitative assessment of tactile allodynia in the rat paw. *J. Neurosci. Methods* 53 (1), 55–63.
- Chen, G., Kim, Y.H., Li, H., Luo, H., Liu, D.L., Zhang, Z.J., Lay, M., Chang, W., Zhang, Y., Q., Ji, R.R., 2017. PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. *Nat. Neurosci.* 20 (7), 917–926.
- Chen, G., Park, C.K., Xie, R.G., Ji, R.R., 2015. Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-beta secretion. *J. Clin. Invest.* 125 (8), 3226–3240.
- Chen, H., Tang, X., Li, J., Hu, B., Yang, W., Zhan, M., Ma, T., Xu, S., 2022. IL-17 crosses the blood-brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine. *J. Headache Pain* 23 (1), 1.
- Davoli-Ferreira, M., de Lima, K.A., Fonseca, M.M., Guimaraes, R.M., Gomes, F.I., Cavallini, M.C., Quadros, A.U., Kusuda, R., Cunha, F.Q., Alves-Filho, J.C., Cunha, T. M., 2020. Regulatory T cells counteract neuropathic pain through inhibition of the Th1 response at the site of peripheral nerve injury. *Pain* 161 (8), 1730–1743.
- Duffy, S.S., Keating, B.A., Perera, C.J., Lees, J.G., Tonkin, R.S., Makker, P.G.S., Carrive, P., Butovsky, O., Moalem-Taylor, G., 2019. Regulatory T cells and their derived cytokine, interleukin-35, reduce pain in experimental autoimmune encephalomyelitis. *J. Neurosci.* 39 (12), 2326–2346.
- Fischer, R., Sendetski, M., Del Rivero, T., Martinez, G.F., Bracchi-Ricard, V., Swanson, K. A., Pruzinsky, E.K., Delguercio, N., Rosalino, M.J., Padutsch, T., Kontermann, R.E., Pfizenmaier, K., Bethea, J.R., 2019. TNFR2 promotes Treg-mediated recovery from neuropathic pain across sexes. *PNAS* 116 (34), 17045–17050.
- Gao, W., Li, F., Zhou, Z., Xu, X., Wu, Y., Zhou, S., Yin, D., Sun, D., Xiong, J., Jiang, R., Zhang, J., 2017. IL-2/Anti-IL-2 complex attenuates inflammation and BBB disruption in mice subjected to traumatic brain injury. *Front. Neurol.* 8, 281.
- Guo, Z., Czerpaniak, K., Zhang, J., Cao, Y.Q., 2021. Increase in trigeminal ganglion neurons that respond to both calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in mouse models of chronic migraine and posttraumatic headache. *Pain* 162 (5), 1483–1499.
- He, W., Long, T., Pan, Q., Zhang, S., Zhang, Y., Zhang, D., Qin, G., Chen, L., Zhou, J., 2019. Microglial NLRP3 inflammasome activation mediates IL-1beta release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model. *J. Neuroinflammation* 16 (1), 78.
- Heldin, C.H., Moustakas, A., 2016. Signaling Receptors for TGF-beta Family Members. *Cold Spring Harb. Perspect. Biol.* 8 (8).
- Hu, R., Zhang, J., Liu, X., Huang, D., Cao, Y.Q., 2021. Low-dose interleukin-2 and regulatory T cell treatments attenuate punctate and dynamic mechanical allodynia in a mouse model of sciatic nerve injury. *J. Pain Res* 14, 893–906.
- Klatzmann, D., Abbas, A.K., 2015. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. *Nat. Rev. Immunol.* 15 (5), 283–294.
- Komai, T., Inoue, M., Okamura, T., Morita, K., Iwasaki, Y., Sumitomo, S., Shoda, H., Yamamoto, K., Fujio, K., 2018. Transforming growth factor-beta and interleukin-10 synergistically regulate humoral immunity via modulating metabolic signals. *Front. Immunol.* 9, 1364.
- Krukowski, K., Eijkelkamp, N., Laumet, G., Hack, C.E., Li, Y., Dougherty, P.M., Heijnen, C.J., Kavelaars, A., 2016. CD8+ T cells and endogenous IL-10 are required for resolution of chemotherapy-induced neuropathic pain. *J. Neurosci.* 36 (43), 11074–11083.
- Kwilasz, A.J., Grace, P.M., Serbedzija, P., Maier, S.F., Watkins, L.R., 2015. The therapeutic potential of interleukin-10 in neuroimmune diseases. *Neuropharmacology* 96 (Pt A), 55–69.
- Lahl, K., Loddenkemper, C., Drouin, C., Freyer, J., Arnason, J., Eberl, G., Hamann, A., Wagner, H., Huehn, J., Sparwasser, T., 2007. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. *J. Exp. Med.* 204 (1), 57–63.
- Laumet, G., Bavencoffe, A., Edralin, J.D., Huo, X.J., Walters, E.T., Dantzer, R., Heijnen, C.J., Kavelaars, A., 2020. Interleukin-10 resolves pain hypersensitivity induced by cisplatin by reversing sensory neuron hyperexcitability. *Pain* 161 (10), 2344–2352.
- Levy, D., Burstein, R., Kainz, V., Jakubowski, M., Strassman, A.M., 2007. Mast cell degranulation activates a pain pathway underlying migraine headache. *Pain* 130 (1–2), 166–176.
- Li, L., Huang, L., Ye, H., Song, S.P., Bajwa, A., Lee, S.J., Moser, E.K., Jaworska, K., Kinsey, G.R., Day, Y.J., Linden, J., Lobo, P.I., Rosin, D.L., Okusa, M.D., 2012. Dendritic cells tolerized with adenosine A(2)AR agonist attenuate acute kidney injury. *J. Clin. Invest.* 122 (11), 3931–3942.
- Littwitz-Salomon, E., Malyshkina, A., Schimmer, S., Dittmer, U., 2018. The cytotoxic activity of natural killer cells is suppressed by IL-10(+) regulatory T cells during acute retroviral infection. *Front. Immunol.* 9, 1947.
- Liu, Y., Teige, I., Birnir, B., Issazadeh-Navikas, S., 2006. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. *Nat. Med.* 12 (5), 518–525.
- Luongo, L., Guida, F., Maione, S., Jacobson, K.A., Salvemini, D., 2021. Adenosine metabotropic receptors in chronic pain management. *Front. Pharmacol.* 12, 651038.
- May, A., Schulte, L.H., 2016. Chronic migraine: risk factors, mechanisms and treatment. *Nature reviews. Neurology* 12 (8), 455–464.
- McIlvried, L.A., Cruz, J.A., Borghesi, L.A., Gold, M.S., 2017. Sex-, stress-, and sympathetic post-ganglionic-dependent changes in identity and proportions of immune cells in the dura. *Cephalalgia* 37 (1), 36–48.
- Messlinger, K., Russo, A.F., 2019. Current understanding of trigeminal ganglion structure and function in headache. *Cephalalgia* 39 (13), 1661–1674.
- Milligan, E.D., Sloane, E.M., Langer, S.J., Hughes, T.S., Jekich, B.M., Frank, M.G., Mahoney, J.H., Levkoff, L.H., Maier, S.F., Cruz, P.E., Flotte, T.R., Johnson, K.W., Mahoney, M.M., Chavez, R.A., Leinwand, L.A., Watkins, L.R., 2006. Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. *Pain* 126 (1–3), 294–308.
- Moore, K.W., de Waal Malefyt, R., Coffman, R.L., O'Garra, A., 2001. Interleukin-10 and the interleukin-10 receptor. *Annu. Rev. Immunol.* 19 (1), 683–765.
- Moreau, J.M., Velegraki, M., Bolyard, C., Rosenblum, M.D., Li, Z., 2022. Transforming growth factor-beta1 in regulatory T cell biology. *Sci. Immunol.* 7 (69), eabi4613.
- Olesen, J., 2008. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. *Pharmacol. Ther.* 120 (2), 157–171.
- Pradhan, A.A., Smith, M.L., McGuire, B., Tarash, I., Evans, C.J., Charles, A., 2014. Characterization of a novel model of chronic migraine. *Pain* 155 (2), 269–274.
- Reuter, U., Bolay, H., Jansen-Olesen, I., Chiarugi, A., Sanchez del Rio, M., Letourneau, R., Theoharides, T.C., Waeber, C., Moskowitz, M.A., 2001. Delayed inflammation in rat meninges: implications for migraine pathophysiology. *Brain* 124 (Pt 12), 2490–2502.
- Schain, A.J., Melo-Carrillo, A., Borsook, D., Grutzendler, J., Strassman, A.M., Burstein, R., 2018. Activation of pial and dorsal macrophages and dendritic cells by cortical spreading depression. *Ann. Neurol.* 83 (3), 508–521.
- Schankin, C.J., Maniyar, F.H., Seo, Y., Kori, S., Eller, M., Chou, D.E., Blecha, J., Murphy, S.T., Hawkins, R.A., Sprenger, T., VanBroeklin, H.F., Goadsby, P.J., 2016. Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. *Brain* 139 (Pt 7), 1994–2001.
- Schmidt, A., Oberle, N., Kramer, P.H., 2012. Molecular mechanisms of treg-mediated T cell suppression. *Front. Immunol.* 3, 51.
- Sharabi, A., Tsokos, M.G., Ding, Y., Malek, T.R., Klatzmann, D., Tsokos, G.C., 2018. Regulatory T cells in the treatment of disease. *Nat. Rev. Drug Discovery* 17 (11), 823–844.
- Shen, K.F., Zhu, H.Q., Wei, X.H., Wang, J., Li, Y.Y., Pang, R.P., Liu, X.G., 2013. Interleukin-10 down-regulates voltage gated sodium channels in rat dorsal root ganglion neurons. *Exp. Neurol.* 247, 466–475.
- Sufka, K.J., Staszko, S.M., Johnson, A.P., Davis, M.E., Davis, R.E., Smitherman, T.A., 2016. Clinically relevant behavioral endpoints in a recurrent nitroglycerin migraine model in rats. *J. Headache Pain* 17, 40.
- Tavares-Ferreira, D., Shiers, S., Ray, P.R., Wangzhou, A., Jeevakumar, V., Sankaranarayanan, I., Cervantes, A.M., Reese, J.C., Chamesian, A., Copits, B.A., Dougherty, P.M., Gereau, R.W., Burton, M.D., Dussor, G., Price, T.J., 2022. Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors. *Sci. Transl. Med.* 14 (632).
- Tipton, A.F., Tarash, I., McGuire, B., Charles, A., Pradhan, A.A., 2016. The effects of acute and preventive migraine therapies in a mouse model of chronic migraine. *Cephalalgia* 36 (11), 1048–1056.
- Wieseler, J., Ellis, A., McPadden, A., Stone, K., Brown, K., Cady, S., Bastos, L.F., Sprunger, D., Rezvani, N., Johnson, K., Rice, K.C., Maier, S.F., Watkins, L.R., 2017. Supradural inflammatory soup in awake and freely moving rats induces facial allodynia that is blocked by putative immune modulators. *Brain Res.* 1664, 87–94.
- Zhang, H., Xia, Y., Ye, Q., Yu, F., Zhu, W., Li, P., Wei, Z., Yang, Y., Shi, Y., Thomson, A. W., Chen, J., Hu, X., 2018. In vivo expansion of regulatory T cells with IL-2/IL-2 antibody complex protects against transient ischemic stroke. *J. Neurosci.* 38 (47), 10168–10179.
- Zhang, J., Czerpaniak, K., Huang, L., Liu, X., Cloud, M.E., Unsinger, J., Hotchkiss, R.S., Li, D., Cao, Y.Q., 2020. Low-dose interleukin-2 reverses behavioral sensitization in multiple mouse models of headache disorders. *Pain* 161 (6), 1381–1398.
- Zhang, J., Li, Z., Chen, F., Liu, H., Wang, H., Li, X., Liu, X., Wang, J., Zheng, Z., 2017. TGF-beta1 suppresses CCL3/4 expression through the ERK signaling pathway and inhibits intervertebral disc degeneration and inflammation-related pain in a rat model. *Exp. Mol. Med.* 49 (9), e379.